Federal Grant Award Summary

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Ohio State University a $648,563 Project Grant effective April 1, 2026, through March 31, 2031, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research initiative will investigate the cellular and neuronal mechanisms by which gut microbiota modulates enterochromaffin cells to promote anxiety-related symptoms in disorders of gut-brain interaction, particularly irritable bowel syndrome (IBS). The research employs advanced in vivo imaging, optogenetics, and behavioral analysis to elucidate how specific bacterial metabolites activate sensory pathways connecting the gastrointestinal tract to the brain through vagal neurons.

The project will deliver fundamental research findings on the molecular signaling mechanisms underlying microbial sensing in the gut-brain circuit, with particular focus on the TRPA1 receptor pathway and its role in anxiety responses. Through bacterial genetic manipulation studies in zebrafish models and analysis of EC-vagal synaptic connectivity, the research aims to identify therapeutic targets for treating visceral pain and anxiety associated with IBS and similar gastrointestinal disorders. This basic research aligns with NIDDK's programmatic priorities to advance understanding of disease mechanisms and support the development of improved prevention and treatment strategies for digestive diseases and their neurological complications.